Armour Thyroid Post-Bariatric Surgery: What Clinicians and Patients Need to Know

Why Bariatric Surgery Changes Thyroid Hormone Absorption

Thyroid hormone replacement depends on predictable dissolution and uptake through the proximal small bowel. Bariatric operations that bypass or dramatically reduce the duodenum and jejunum therefore change the pharmacokinetics of every oral thyroid preparation, including Armour Thyroid.

The Anatomy Problem

Roux-en-Y gastric bypass (RYGB) creates a small gastric pouch and routes ingested material directly into the mid-jejunum, bypassing roughly 100 to 150 cm of small intestine where most T4 and T3 absorption normally occurs. A 2014 review in Obesity Surgery documented that hypothyroid patients post-RYGB required levothyroxine dose increases averaging 25 to 74 percent compared with their pre-operative requirements, depending on the degree of intestinal bypass [1]. Sleeve gastrectomy (SG) reduces gastric volume without rerouting the bowel, producing a smaller and more variable effect on absorption. Adjustable gastric banding generally has minimal impact on drug absorption.

How NDT Differs From Levothyroxine in This Context

Armour Thyroid tablets contain T4 and T3 bound within desiccated porcine thyroid gland matrix. The tablet must first disintegrate, then the hormone must dissolve in gastrointestinal fluid, and finally it must cross the enterocyte brush border. All three steps are affected after RYGB:

• Disintegration is slowed when the stomach pouch produces less acid (achlorhydria is common in the first 12 months post-RYGB).
• Dissolution depends on a normal pH gradient across the proximal gut, which is disrupted when chyme bypasses the duodenum.
• Absorption of T3 is faster and more complete than T4 under normal conditions, but T3's shorter half-life of roughly 24 hours means that even modest absorption variability translates into wider swings in free T3 levels throughout the day.

Because Armour Thyroid delivers both T4 and T3, the clinician must monitor both fractions, not just TSH, to ensure stable replacement after bariatric surgery.

Gastric Acid and Achlorhydria

Proton-pump inhibitor (PPI) use, which is nearly universal for the first 3 to 6 months after RYGB, compounds the absorption problem. PPIs independently reduce levothyroxine absorption by up to 40 percent in susceptible patients [2]. The same mechanism affects NDT. Patients who continue long-term PPI therapy after bariatric surgery should be flagged for closer TSH surveillance.

The Evidence Base for NDT vs. Levothyroxine After Bariatric Surgery

No randomized controlled trial has evaluated Armour Thyroid specifically in a post-bariatric population. The evidence field requires extrapolation from two bodies of literature: general NDT-vs-LT4 trials and bariatric-specific levothyroxine pharmacokinetic studies.

The Hoang 2013 Trial

The most-cited head-to-head comparison of NDT and levothyroxine is Hoang et al., published in the Journal of Clinical Endocrinology and Metabolism in 2013 (N=70, crossover design, 16 weeks per arm) [3]. Patients treated with NDT achieved equivalent TSH suppression to levothyroxine-treated patients. 49 percent of participants preferred NDT over levothyroxine at study end, citing better mood and cognitive function. The authors concluded: "Treatment with desiccated thyroid extract resulted in greater weight loss and patients preferred DTE over L-T4, although both preparations resulted in similar thyroid hormone levels." This trial enrolled non-surgical outpatients, so the preference signal may not translate cleanly to patients whose absorption kinetics have been surgically altered.

Bariatric-Specific LT4 Pharmacokinetics

A 2011 study by Rubio et al. In Obesity Surgery (N=45) measured serial TSH values in hypothyroid patients before and after RYGB [4]. At 12 months post-surgery, 67 percent required a dose increase averaging 37 mcg of LT4 per day. Because Armour Thyroid 1 grain contains approximately 38 mcg T4 equivalent, this data point suggests that many post-RYGB patients on NDT will need roughly one additional grain per day, though individual variation is wide.

Soft-Gel and Liquid Formulations as a Reference Point

Tirosint-SOL (liquid levothyroxine) and Tirosint soft-gel capsules have both demonstrated superior absorption compared with tablet LT4 in patients with conditions that impair tablet dissolution, including achlorhydria and post-bariatric anatomy [5]. No equivalent liquid NDT product is FDA-approved, which is a genuine clinical limitation. Clinicians who decide that the post-bariatric absorption barrier is too unpredictable for tablet NDT have no liquid NDT alternative and may need to transition the patient to liquid LT4, accepting the loss of the T3 component (or adding liothyronine separately).

Pre-Operative Assessment for Patients on Armour Thyroid

Optimizing thyroid status before bariatric surgery reduces peri-operative risk. Hypothyroidism is associated with impaired wound healing, bradycardia under anesthesia, and increased sensitivity to opioid sedation [6].

Baseline Lab Panel

Obtain the following within 60 days of the scheduled surgery date:

• TSH (goal 0.5 to 2.5 mIU/L)
• Free T4
• Free T3 (especially relevant for NDT users given the T3 component)
• Total T3 if free T3 assay is unavailable
• Anti-TPO antibody if autoimmune etiology has not been confirmed

A TSH above 10 mIU/L at the pre-op visit warrants surgical delay until euthyroid status is re-established, per the 2021 American Thyroid Association (ATA) surgical guidelines [7].

Dose Optimization Window

If a patient is sub-optimally dosed on Armour Thyroid pre-operatively, adjust the dose and recheck TSH in 6 to 8 weeks. Do not use bariatric surgery as a reason to defer optimization; an euthyroid patient entering surgery absorbs peri-operative medications more predictably than one who is overtly hypothyroid.

Intra-Operative and Immediate Post-Operative Management

Morning-of-Surgery Dosing

Armour Thyroid should be taken on the morning of surgery with a small sip of water even if the patient is otherwise NPO (nothing by mouth), provided surgical team approval. T3 has a half-life of roughly 1 day; missing a single dose produces measurable free T3 decline within 12 to 18 hours in patients whose T3 depends entirely on exogenous NDT rather than peripheral conversion.

Post-Operative Days 1 to 14

Swallowing tablets may be difficult or contraindicated in the first days after RYGB or sleeve gastrectomy. Options include:

1. Crushing Armour Thyroid tablets and mixing with a small amount of water. The FDA has not approved this route, and the pharmacokinetic data for crushed NDT are sparse, but the approach is widely used clinically. The tablet matrix is not an extended-release formulation, so crushing does not create a rapid-release safety problem.
2. Temporary transition to liquid LT4 (Tirosint-SOL). This is the approach most endocrinologists prefer for the first 4 to 6 weeks. The dose conversion requires care: 1 grain of Armour Thyroid contains roughly 38 mcg T4 plus 9 mcg T3. Because T3 is approximately three to five times as potent as T4, 1 grain NDT is often considered bioequivalent to approximately 60 to 65 mcg LT4 for TSH-suppression purposes, though published conversion tables vary.
3. IV levothyroxine in the ICU or step-down setting, dosed at 70 to 80 percent of the oral equivalent, for patients who are NPO for more than 72 hours.

Long-Term Dosing Strategy After Bariatric Surgery

Once the patient is tolerating oral intake, the key question is whether to return to Armour Thyroid or transition permanently to a different formulation.

Factors Favoring Continued NDT Use

• Patient had clear subjective benefit on NDT before surgery (documented in chart)
• Pre-op TSH was consistently within target on NDT
• Procedure was sleeve gastrectomy rather than RYGB (less absorption disruption)
• Patient is willing to take NDT separately from food, calcium, iron, and PPIs by at least 60 minutes

Factors Favoring Transition to Liquid or Soft-Gel LT4

• Procedure was RYGB or duodenal switch (high malabsorption risk)
• TSH becomes erratic despite adherence post-op
• Patient requires high-dose PPI long term
• Free T3 runs persistently elevated (above 4.2 pg/mL) on NDT, suggesting T3 accumulation due to altered clearance

The HealthRX clinical team uses the following decision framework for post-bariatric NDT management. At the 6-week post-op visit, check TSH, free T4, and free T3. If TSH is above 3.0 mIU/L on the same pre-op NDT dose, increase by one-half grain (30 mg) and recheck in 6 weeks. If TSH remains above 3.0 mIU/L after two successive increases totaling one full grain, consider transition to liquid LT4 with possible liothyronine supplementation. If TSH is below 0.3 mIU/L and free T3 is elevated, reduce NDT by one-half grain before assuming over-replacement.

Empirical Dose Increase After RYGB

Based on the pharmacokinetic literature cited above, a practical starting point is to increase the total daily Armour Thyroid dose by 25 to 30 percent immediately after RYGB and recheck TSH at 6 weeks, rather than waiting for an elevated TSH to prompt action. This proactive approach reduces the cumulative time the patient spends hypothyroid during the critical post-surgical healing period.

Timing and Administration Rules

The absorption rules that apply to levothyroxine apply with equal or greater force to NDT post-bariatric surgery:

• Take Armour Thyroid on an empty stomach, at least 30 to 60 minutes before the first meal.
• Separate from calcium carbonate by at least 4 hours (calcium reduces T4 absorption by up to 20 percent) [8].
• Separate from ferrous sulfate by at least 2 hours.
• Separate from cholestyramine and other bile-acid sequestrants by at least 4 hours.
• Coffee and espresso, even black, can reduce levothyroxine absorption by 25 to 35 percent [9]; the same interaction likely applies to NDT.

Monitoring Protocol Post-Bariatric Surgery

Recommended Lab Schedule

| Timepoint | Labs | |---|---| | Pre-op (within 60 days) | TSH, free T4, free T3 | | 6 weeks post-op | TSH, free T4, free T3 | | 3 months post-op | TSH, free T4 | | 6 months post-op | TSH, free T4, free T3 | | 12 months post-op | TSH, free T4, free T3, anti-TPO if not previously confirmed | | Annually thereafter | TSH, free T4 |

Free T3 monitoring matters more for NDT users than for pure LT4 users because the exogenous T3 in Armour Thyroid contributes directly to circulating T3 levels, not through peripheral conversion. A persistently elevated free T3 above 4.2 pg/mL on NDT should prompt dose reduction even if TSH appears normal, because T3 excess increases cardiovascular risk, particularly atrial fibrillation.

TSH Target After Bariatric Surgery

The 2019 American Association of Clinical Endocrinologists (AACE) and American Thyroid Association guidelines recommend a TSH target of 0.4 to 4.0 mIU/L for most adults on thyroid replacement, with tighter targets (0.5 to 2.5 mIU/L) for patients under 60 with cardiovascular risk factors [10]. Post-bariatric patients often have active cardiovascular risk factors. Most HealthRX-affiliated endocrinologists target 0.5 to 2.5 mIU/L in this population.

Special Populations Within Post-Bariatric Patients

Women of Reproductive Age

Bariatric surgery is performed most commonly in women aged 18 to 45, many of whom are planning pregnancy. Hypothyroidism during the first trimester is associated with reduced fetal IQ and increased miscarriage risk. The pre-conception TSH target for women on thyroid replacement is below 2.5 mIU/L per the 2017 ATA guidelines on thyroid disease in pregnancy [11]. Women who become pregnant post-bariatric surgery on Armour Thyroid typically need a 25 to 50 percent dose increase in the first trimester, on top of any post-surgical dose increase already made. TSH should be checked every 4 weeks through 20 weeks of gestation.

Patients With Type 2 Diabetes

Many bariatric candidates have type 2 diabetes (T2D). Hypothyroidism worsens insulin resistance and dyslipidemia. After RYGB, T2D often remits rapidly; as blood glucose normalizes, the previously elevated TBG (thyroid-binding globulin) associated with hyperinsulinemia also normalizes, which can shift the free-to-total thyroid hormone ratio and affect interpretation of free T4 and free T3 values. Monitor more frequently (every 6 weeks for the first 6 months) in patients whose T2D is in rapid remission.

Patients on Semaglutide or Other GLP-1 Receptor Agonists

GLP-1 receptor agonists are increasingly prescribed before and after bariatric surgery for additional weight management. Semaglutide slows gastric emptying substantially. Delayed gastric emptying may reduce peak T4 and T3 absorption after NDT dosing [12]. The effect size has not been quantified in a dedicated pharmacokinetic study, but clinicians should maintain heightened TSH surveillance when semaglutide is initiated in a post-bariatric patient already on Armour Thyroid.

Drug Interactions Particularly Relevant Post-Bariatric Surgery

Bariatric patients are often on multiple supplements and medications simultaneously, creating a complex interaction environment.

Calcium and Vitamin D Supplementation

Post-bariatric protocols universally require calcium supplementation, typically 1,200 to 1,500 mg elemental calcium daily in divided doses. Calcium carbonate reduces thyroid hormone absorption; calcium citrate has a smaller effect but is still measurable [8]. Patients must be counseled explicitly to take Armour Thyroid at least 4 hours before or after their first calcium dose. This counseling should be documented in the chart at every post-op visit for the first year.

Proton-Pump Inhibitors

As noted above, PPIs reduce NDT absorption. If a patient remains on a PPI beyond the standard 6-month post-operative window, reassess TSH. Switching to an H2 blocker (famotidine 20 mg twice daily) produces less absorption interference and may be sufficient for acid suppression in the non-ulcer post-bariatric patient.

Iron Supplementation

Iron deficiency is common after RYGB due to reduced gastric acid and bypassed duodenum, the primary site of iron absorption. Iron supplementation is therefore standard, and ferrous sulfate 325 mg daily is the typical starting dose. Ferrous sulfate chelates T4 in the gut and reduces absorption by up to 30 percent [13]. Patients should be told: take thyroid medicine first thing in the morning, wait at least 2 hours, then take iron.

When to Consider Stopping Armour Thyroid After Bariatric Surgery

Some patients develop persistently erratic TSH values despite confirmed adherence, correct timing, and absence of major drug interactions. In these cases, continuing NDT is not always the right clinical decision.

Criteria for transitioning off NDT post-bariatric surgery include:

• Two or more TSH values above 5.0 mIU/L 6 weeks apart on a dose that was previously adequate
• Free T3 persistently outside the normal range in either direction without an obvious dose explanation
• Patient reports symptoms of both hyper- and hypothyroidism on alternating weeks, suggesting absorption variability
• Upcoming pregnancy where stable thyroid levels are especially critical

When transitioning, calculate the LT4 equivalent carefully. A common conversion error is to use a 1:1 mcg-for-mcg substitution from NDT T4 content alone, omitting the T3 contribution. A 2-grain (120 mg) daily Armour Thyroid dose contains approximately 76 mcg T4 and 18 mcg T3. Using a T3:T4 potency ratio of 3:1 (a conservative estimate), the T3 component contributes roughly 54 mcg LT4-equivalent. Total LT4-equivalent: approximately 130 mcg, not 76 mcg. Starting at 76 mcg LT4 would leave the patient significantly under-replaced.

Patient Education Points for Post-Bariatric NDT Use

Patients frequently receive conflicting advice from their bariatric surgeon, their endocrinologist, and online support communities. A clear, brief education checklist reduces confusion:

1. Take Armour Thyroid on an empty stomach, 30 to 60 minutes before any food or drink except water.
2. Take all calcium supplements at least 4 hours after the thyroid dose.
3. Take iron supplements at least 2 hours after the thyroid dose.
4. Do not miss doses, especially in the first 6 months after surgery when your gut is still adapting.
5. Tell your doctor about any new medication, supplement, or significant dietary change.
6. Get your TSH checked at every scheduled post-bariatric follow-up, even if you feel fine. Post-surgical hypothyroidism can be subtle.
7. Pregnancy after bariatric surgery requires immediate TSH testing and likely dose adjustment.